Should Urogenital Atrophy in Breast Cancer Survivors Be Treated with Topical Estrogens?

Abstract

Abstract Learning Objectives After completing this course, the reader will be able to: Describe the urogenital consequences of antiestrogen treatment among women with a prior diagnosis of breast cancer and the effects that these side effects have on quality of life and medication compliance.Advise on the standard treatment of urogenital atrophy, including alternatives to topical estrogen replacement, in the non–breast cancer and breast cancer populations.Evaluate the evidence for the current recommendations of estrogen replacement therapy among women with a prior diagnosis of breast cancer. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com Breast cancer survivors represent a unique patient population with a high prevalence of menopausal symptoms. Given the improved longevity of cancer patients, the consequences of menopause have become an increasingly important and challenging management issue. To date, considerable attention has been paid to the management of menopausal vasomotor symptoms and bone health among breast cancer patients. As a result, numerous nonhormonal treatment options have been developed for the management of these issues. The treatment of urogenital symptoms among this population is poorly understood and relatively understudied. Although systemic or topical estrogen replacement is the most effective method for treating hypoestrogenemic urogenital symptoms, women with a prior diagnosis of breast cancer are cautioned from taking exogenous estrogens in order to avoid a potential contribution to recurrent breast cancer risk. This review focuses on the urogenital consequences of estrogen deprivation therapy in breast cancer patients and provides practitioners with a simple guide of current and future strategies for managing these symptoms.